Sofia Necander
BioPharmaceuticals R&D
Goeteborg, O, Sweden
Goeteborg, O, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Efficacy of benralizumab in reducing cough and/or dyspnea frequency, and improving cough-specific health-related quality of life in patients with severe eosinophilic asthma in Asia.
Journal: Therapeutic advances in respiratory disease
Published: August 28, 2026
Patients' perspectives of eosinophilic granulomatosis with polyangiitis within the context of a clinical trial.
Journal: EULAR rheumatology open
Published: June 29, 2026
Deep Learning Improves Sensitivity to Change in Sinus Computed Tomography: Evidence From Two Randomized Controlled Trials.
Journal: International forum of allergy & rhinology
Published: March 01, 2026
Efficacy and clinical remission in patients with severe asthma and blood eosinophil counts ≥150 cells/μl treated with benralizumab: a sub-analysis of the Phase 3 MIRACLE study
Journal: Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
Published: October 10, 2025
Benralizumab reduces sputum ANCA in patients with eosinophilic granulomatosis with polyangiitis.
Journal: ERJ open research
Published: August 21, 2025
Two-year efficacy and safety of anti-interleukin-5/receptor therapy for eosinophilic granulomatosis with polyangiitis.
Journal: Annals of the rheumatic diseases
Published: March 11, 2025
The Effect of Benralizumab and Mepolizumab on Use of Oral Glucocorticoids in Patients With Eosinophilic Granulomatosis With Polyangiitis.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: February 07, 2025
Discontinuation of Oral Glucocorticoids and Achievement of Remission in Patients With Eosinophilic Granulomatosis With Polyangiitis Treated With Benralizumab or Mepolizumab.
Journal: ACR open rheumatology
Published: January 15, 2025
Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis.
Journal: The New England journal of medicine
Published: February 23, 2024
Physical activity end-points in trials of chronic respiratory diseases: summary of evidence.
Journal: ERJ open research
Published: September 06, 2021
Characterization of Clinical Absorption, Distribution, Metabolism, and Excretion and Pharmacokinetics of Velsecorat Using an Intravenous Microtracer Combined with an Inhaled Dose in Healthy Subjects.
Journal: Drug metabolism and disposition: the biological fate of chemicals
Published: August 04, 2021
Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial.
Journal: The Journal of allergy and clinical immunology
Published: May 24, 2021
Last Updated: 09/26/2026